Your browser is no longer supported. Please, upgrade your browser.
HCW Biologics Inc.
Index- P/E- EPS (ttm)-0.22 Insider Own43.40% Shs Outstand35.73M Perf Week-4.55%
Market Cap94.89M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float8.92M Perf Month-6.51%
Income-7.90M PEG- EPS next Q- Inst Own0.50% Short Float1.74% Perf Quarter-31.75%
Sales4.10M P/S23.15 EPS this Y9.10% Inst Trans- Short Ratio0.05 Perf Half Y-
Book/sh1.51 P/B1.81 EPS next Y- ROA- Target Price- Perf Year-
Cash/sh1.15 P/C2.37 EPS next 5Y- ROE- 52W Range2.36 - 7.78 Perf YTD-56.67%
Dividend- P/FCF- EPS past 5Y- ROI34.90% 52W High-64.89% Beta-
Dividend %- Quick Ratio18.20 Sales past 5Y- Gross Margin- 52W Low15.68% ATR0.42
Employees40 Current Ratio18.20 Sales Q/Q- Oper. Margin- RSI (14)43.37 Volatility6.79% 12.69%
OptionableNo Debt/Eq0.00 EPS Q/Q-36.60% Profit Margin- Rel Volume0.02 Prev Close2.82
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume2.96M Price2.73
Recom- SMA20-15.13% SMA50-11.72% SMA200-27.97% Volume66,831 Change-3.19%
Nov-12-21 07:00AM  
Oct-28-21 02:45PM  
Oct-27-21 07:00AM  
Oct-20-21 07:30AM  
Aug-31-21 09:08AM  
Aug-25-21 09:14AM  
Aug-24-21 07:32AM  
Aug-17-21 07:32AM  
Aug-13-21 07:10AM  
Jul-22-21 04:05PM  
Jul-19-21 06:39PM  
HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead product include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Byam RebeccaChief Financial OfficerNov 23Option Exercise0.1427,0003,78089,000Nov 26 12:17 PM